Apparent Elevation of Whole-Blood Tacrolimus Concentrations Following High-Dose Intravenous Immunoglobulin Therapy in Kidney Transplant Recipients
Background: The effect of massive immunoglobulin G (IgG) elevation on highly protein-bound tacrolimus (TAC) after high-dose intravenous immunoglobulin (IVIG) therapy remains uncharacterized. Misinterpreting IVIG-induced whole-blood TAC elevation as increased unbound fraction risks underdosing and rejection in donor-specific antibody-positive kidney transplant recipients. The aim of this study was to investigate the interaction between IVIG-induced IgG elevation and TAC during preoperative desensitization. Methods: This retrospective study compared TAC trough levels (C 0 ), area under the concentration–time curve from 0 to 24 hours (AUC 0–24 ), TAC C 0 /dose (C 0 /D), TAC AUC 0–24 /dose (AUC 0–24 /D), and serum IgG levels predesensitization and postdesensitization among 3 groups: IVIG [high-dose IVIG plus plasmapheresis (PP), n = 12], PP only (n = 7), and control (n = 68). Results: Following IVIG, median whole blood TAC C 0 rose from 6.5 to 9.3 ng/mL and AUC 0–24 from 238.2 to 325.8 ng·hours/mL. Accordingly, serum IgG levels increased from 968 (898–1396) to 2647 (2349–2927) mg/dL. A linear mixed model confirmed that an increase in serum IgG levels was independently associated with an elevated TAC AUC 0–24 /D. This apparent TAC AUC 0–24 /D increase peaked at 1.3-fold and persisted for 2 weeks; however, no clinical evidence of TAC toxicity (eg, hyperkalemia) was observed, suggesting an unlikely rise in the unbound concentration. Conclusions: IVIG induced an apparent elevation in whole-blood TAC concentrations, mediated by elevated serum IgG levels. Because this elevation theoretically may not reflect an increase in the unbound fraction, empirical dose reductions based solely on whole-blood levels risk compromising immunosuppression. A vigilant therapeutic drug monitoring strategy is essential to account for the protein-binding interaction and potentially optimize immunosuppression in high-risk patients.
Authors
- Tatsu Tanabe (ORCID: https://orcid.org/0009-0003-6167-9774)
- Toyoshi Seito (ORCID: https://orcid.org/0000-0002-8417-9495)
- Hideki Kanou
- Hajime Sasaki (ORCID: https://orcid.org/0000-0001-7639-0912)
- Asuka Yamamoto
- Takashi Tsujimoto (ORCID: https://orcid.org/0009-0002-0631-7466)
Institutions
- Sapporo City General Hospital (JP)
Publication Details
- Journal
- Therapeutic Drug Monitoring
- Published
- 2026-07-28
- DOI
- https://doi.org/10.1097/ftd.0000000000001512
- Primary Topic
- Platelet Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00